UNSPSC 51323002: Levocarnitine

This classification denotes a nutritional supplement, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0G389FZZ9M. European Medicines Agency schedules Carnitine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06134MIG. Carnitine generally arises in the molecular formula C7H15NO3.

UNSPSC 51323002 Levocarnitine, a Commodity code, addresses pharmaceutical ingredients and finished medications procured by state and local health and emergency services agencies. State and local governments buy levocarnitine and related pharmaceutical products under this code primarily for emergency medical services, hospital systems, and health benefit programs; the scope extends to generic multi-source pharmaceuticals, over-the-counter products, and advanced life support medications supplied through established wholesaler networks. Issuing bodies span city emergency response departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across state and local members. The City of Tampa's Fire Rescue division, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) are recent active buyers. Procurement methods vary from sealed competitive bids for immediate emergency medication supply to requests for information gathering vendor capability for direct-to-manufacturer pharmacy initiatives and multistate RFPs establishing framework contracts with multiple awards.

Activity is concentrated in Florida, Texas, and Minnesota. The City of Tampa issued an IFB (Bid No. 26-P-00188) for Advanced Life Support Medications on April 24, 2026, with a response date of April 8, 2026, and an estimated contract value of $40,000.00; the solicitation requires supply of four specific medication line items with nine-month minimum expiration dates and delivery within ten calendar days, includes a 5 percent Small Local Business Enterprise bid discount, and runs one year with two optional one-year renewals plus three unilateral 30-day extensions. The Minnesota Department of Administration's MMCAP issued an RFP (S1070000015802) for Generic Multi Source Pharmaceuticals and OTC Products on January 20, 2026, with a March 26, 2026 response deadline, establishing two-year contracts effective July 1, 2026, across authorized wholesalers serving state and local facilities in Minnesota and Oregon. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in March 2026 to gather vendor information on direct-to-manufacturer prescription programs, signaling early-stage procurement strategy development for a potential formal RFP.